首页> 外文期刊>British Journal of Clinical Pharmacology >The disposition of oral amodiaquine in Papua New Guinean children with falciparum malaria.
【24h】

The disposition of oral amodiaquine in Papua New Guinean children with falciparum malaria.

机译:巴布亚新几内亚患有恶性疟疾的儿童口服阿莫地喹的处置。

获取原文
获取原文并翻译 | 示例
           

摘要

AIMS: We assessed the disposition of oral amodiaquine (AQ) and CYP2C8 polymorphism in 20 children with falciparum malaria. METHODS: AQ and DEAQ concentrations were determined with SPE-HPLC method. CYP2C8 genotypes were assessed by PCR-RFLP method. RESULTS: AQ was not detectable beyond day 3 postdose. Cmax for DEAQ was reached in 3.0 days. The mean values for t1/2, MRT, and AUCtotal were 10.1 days, 15.5 days and 4512.6 microg l(-1) day, respectively. All the children were CYP2C8* homozygous. CONCLUSION: Our data are consistent with those previously reported, and the AQ regimen seems pharmacokinetically adequate in the absence of CYP2C8 polymorphism.
机译:目的:我们评估了20名儿童恶性疟疾患者口服阿莫地喹(AQ)和CYP2C8基因多态性的分布。方法:采用SPE-HPLC法测定AQ和DEAQ浓度。 CYP2C8基因型通过PCR-RFLP方法评估。结果:在给药后第3天后仍未检测到AQ。 DEAQ的Cmax在3.0天内达到。 t1 / 2,MRT和AUCtotal的平均值分别为10.1天,15.5天和4512.6 microg l(-1)天。所有儿童均为CYP2C8 *纯合子。结论:我们的数据与先前报道的一致,并且在没有CYP2C8多态性的情况下,AQ方案在药代动力学上似乎是足够的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号